Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Website: cyclerion.com


  • Good financial results growth rate 50.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (18.8%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -602.0% (LTM)
  • Share price is 172.0% higher than minimum and 49.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (0.1x vs 0.2x)

Key Financials (Download financials)

Ticker: CYCN
Share price, USD:  (+3.9%)3.21
year average price 2.07  


year start price 3.11 2025-06-13

max close price 3.64 2025-07-11

min close price 1.18 2025-12-30

current price 3.21 2026-06-12
Common stocks: 2 176 050

Dividend Yield:  0.0%
EV / Sales: -1.5x
Margin (EBITDA LTM / Revenue): -1 050.0%

Target EV / EBITDA (hist percentile): 0.2x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 7
Net Debt ($m): -13
EV (Enterprise Value): -6
EBITDA LTM (млн $): -42
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-24seekingalpha.com

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

2024-12-17globenewswire.com

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

2024-08-07globenewswire.com

Regina Graul, Ph.D., Promoted to Chief Executive Officer
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-05 2024-11-14 2024-08-07 2024-05-07 2023-11-13 2023-07-28 2023-05-12 2022-11-03
acceptedDate 2025-11-12 16:30:53 2025-08-05 16:30:55 2025-03-04 16:15:24 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58 2022-02-24 16:06:04 2021-02-25 07:35:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 875 000 93 000 2M 194 000 0 0 0 0 0 0 297 000 0 3M 2M
costOfRevenue 0 0 0 0 0 0 0 0 0 0 6M 0 0 56M
grossProfit 875 000 93 000 2M 194 000 0 0 0 0 0 0 -5M 0 3M -54M
grossProfitRatio 1 1 1 0 0 0 0 0 0
researchAndDevelopmentExpenses 348 000 56 000 286 000 81 000 105 000 44 000 2M 580 000 886 000 4M 6M 7M 38M 56M
generalAndAdministrativeExpenses 2M 2M 5M 1M 1M 2M 8M 2M 3M 3M 13M 4M 21M 29M
sellingAndMarketingExpenses 0 0 0 0 0 0 200 000 0 0 0 400 000 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 2M 5M 1M 1M 2M 8M 2M 3M 3M 13M 4M 21M 29M
otherExpenses 0 0 0 0 0 0 3M 0 0 0 -6M 0 259 000 -58M
operatingExpenses 2M 2M 6M 1M 1M 2M 13M 3M 4M 7M 13M 11M 59M 27M
costAndExpenses 2M 2M 6M 1M 1M 2M 13M 3M 4M 7M 19M 11M 59M 84M
interestIncome 30 000 31 000 208 000 42 000 62 000 76 000 358 000 107 000 62 000 0 294 000 0 0 588 000
interestExpense 0 0 0 0 0 0 0 0 0 88 000 0 111 000 16 000 0
depreciationAndAmortization 0 0 0 0 0 43 276 65 000 7M 0 0 65 000 0 472 000 2M
ebitda -976 000 -2M -4M -1M -1M -2M -10M 593 000 -4M -7M -18M -11M -54M -81M
ebitdaratio -1.115 -17.978 -5.814 0 0 0 0 0 0
operatingIncome -1M -2M -4M -1M -1M -2M -13M -6M -4M -7M -19M -11M -55M -81M
operatingIncomeRatio -1.15 -17.978 -5.814 0 0 0 0 0 0
totalOtherIncomeExpensesNet 30 000 1M 571 000 405 000 62 000 76 000 358 000 -3M 62 000 88 000 294 000 111 000 4M 3M
incomeBeforeTax -976 000 -324 000 -3M -723 000 -1M -2M -13M -6M -4M -7M -18M -10M -52M -78M
incomeBeforeTaxRatio -1.115 -3.484 -3.727 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 -43 276 0 -17M 0 -176 000 0 -222 000 0 0
netIncome -976 000 -324 000 -3M -723 000 -1M -2M -5M 8M -4M -7M -44M -10M -52M -78M
netIncomeRatio -1.115 -3.484 -3.727 0 0 0 0 0 0
eps -0.3 -0.11 -1.21 -0.29 -0.53 -0.62 -8.99 -3.36 -1.83 -3.11 -20.15 -0.24 -26.4 -47.8
epsdiluted -0.3 -0.11 -0.29 -0.53 -0.62 -3.36 -1.83 -3.11 -0.24
weightedAverageShsOut 3M 3M 3M 3M 3M 2M 2M 2M 2M 2M 2M 43M 2M 2M
weightedAverageShsOutDil 3M 3M 3M 3M 3M 2M 2M 2M 2M 2M 2M 43M 2M 2M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-05 2023-03-22 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 208 000 358 000 294 000 -16 000 588 000
ebit -4M -10M -19M -54M -83M
nonOperatingIncomeExcludingInterest 0 -3M 0 -881 000 2M
netIncomeFromContinuingOperations -3M -13M -18M -52M -78M
netIncomeFromDiscontinuedOperations 0 7M -26M 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -3M -13M -18M -52M -78M
epsDiluted -1.21 -8.99 -20.15 -26.4 -47.8

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-05 2024-11-14 2024-08-07 2024-05-07 2023-11-13 2023-07-28 2023-05-12 2022-11-03
acceptedDate 2025-11-12 16:30:53 2025-08-05 16:30:55 2025-03-04 16:15:24 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58 2022-02-24 16:06:04 2021-02-25 07:35:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 5M 3M 3M 3M 5M 6M 8M 9M 6M 7M 13M 20M 54M 54M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 5M 3M 3M 3M 5M 6M 8M 9M 6M 7M 13M 20M 54M 54M
netReceivables 100 000 525 000 556 000 44 000 0 0 0 0 0 96 000 96 000 227 000 100 000 127 000
inventory 0 0 0 0 0 0 0 0 0 567 000 0 0 928 000 0
otherCurrentAssets 397 000 489 000 16 000 632 000 127 000 318 000 11 000 30 000 428 000 503 000 537 000 488 000 468 000 2M
totalCurrentAssets 5M 4M 4M 4M 5M 6M 8M 10M 7M 8M 15M 22M 55M 59M
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 1M 1M 1M 1M 1M 50M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 5M 5M 5M 5M 5M 5M 5M 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 5M 0 0 0 0 0 0 0 2M 2M 2M 2M 2M 7M
totalNonCurrentAssets 5M 5M 5M 5M 5M 5M 5M 5M 3M 3M 3M 3M 4M 57M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 10M 9M 10M 9M 10M 11M 13M 15M 10M 11M 18M 25M 59M 115M
accountPayables 480 000 462 000 390 000 304 000 651 000 741 000 1M 814 000 2M 4M 3M 2M 2M 1M
shortTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 4M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 397 000 338 000 63 000 396 000 631 000 700 000 102 000 2M 3M 4M 68 000 7M 7M 176 000
totalCurrentLiabilities 877 000 800 000 725 000 700 000 1M 1M 2M 2M 5M 8M 8M 9M 11M 17M
longTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 4M 0 -2M 0 0
totalNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 4M 0 2M 0 39M
otherLiabilities 0 0 0 0 0 0 0 0 0 -4M 0 -2M 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 42M
totalLiabilities 877 000 800 000 725 000 700 000 1M 1M 2M 2M 5M 8M 8M 9M 11M 56M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
retainedEarnings -270M -269M -267M -268M -267M -266M -264M -263M -270M -266M -259M -252M -215M -163M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 -16 000 -12 000 -18 000 -16 000 -19 000 -20 000 -28 000 -23 000 -27 000
othertotalStockholdersEquity 280M 278M 276M 276M 276M 276M 275M 270M 268M
totalStockholdersEquity 10M 9M 9M 8M 9M 10M 11M 13M 5M 4M 10M 17M 48M 59M
totalEquity 10M 9M 9M 8M 9M 10M 11M 13M 5M 4M 10M 17M 48M 59M
totalLiabilitiesAndStockholdersEquity 10M 9M 9M 10M 11M 15M 10M 11M 25M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 10M 9M 10M 9M 10M 11M 13M 15M 10M 11M 18M 25M 59M 115M
totalInvestments 0 5M 5M 5M 5M 5M 5M 5M 0 0 0 0 0 0
totalDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 46M
netDebt -5M -3M -3M -3M -5M -6M -8M -9M -6M -7M -13M -20M -54M -9M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-05 2023-03-22 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 556 000 0 96 000 100 000 127 000
otherReceivables 0 0 0 0 0
prepaids 421 000 442 000 805 000 0 2M
totalPayables 390 000 1M 3M 2M 1M
otherPayables 0 0 0 0 0
accruedExpenses 272 000 786 000 5M 2M 9M
capitalLeaseObligationsCurrent 0 0 0 0 3M
capitalLeaseObligationsNonCurrent 0 0 0 0 39M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 276M 270M 263M 223M
otherTotalStockholdersEquity 276M 0 -0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN CYCN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-05 2024-11-14 2024-08-07 2024-05-07 2023-11-13 2023-07-28 2023-05-12 2022-11-03
acceptedDate 2025-11-12 16:30:53 2025-08-05 16:30:55 2025-03-04 16:15:24 2024-11-14 16:30:24 2024-08-07 06:45:21 2024-05-07 16:30:34 2024-03-05 16:15:38 2023-11-13 16:30:32 2023-07-28 16:48:38 2023-05-11 19:37:17 2023-03-22 16:55:38 2022-11-03 17:00:58 2022-02-24 16:06:04 2021-02-25 07:35:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -976 000 -324 000 -3M -723 000 -1M -2M -13M 8M -4M -7M -18M -10M -52M -78M
depreciationAndAmortization 0 0 0 0 0 0 0 0 0 0 65 000 0 472 000 2M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 118 000 114 000 625 000 138 000 184 000 181 000 0 159 000 379 000 426 000 0 2M 10M 15M
changeInWorkingCapital 594 000 -293 000 -2M 478 000 32 000 -510 000 -5M -2M -3M 314 000 -3M -1M 1M -8M
accountsReceivables 425 000 56 000 -556 000 -44 000 0 0 96 000 0 96 000 0 4000 0 27 000 1M
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 18 000 -21 000 -445 000 184 000 -91 000 -456 000 -2M -1M -2M 955 000 1M -1M 393 000 -1M
otherWorkingCapital 151 000 -328 000 -537 000 338 000 123 000 -54 000 -3M -1M -788 000 -641 000 -4M 41 000 988 000 -8M
otherNonCashItems 0 0 -363 000 -2M 0 637 000 -4M -12M 0 0 -20M 0 4M -4M
netCashProvidedByOperatingActivities -264 000 -503 000 -4M -2M -1M -2M -21M -7M -7M -6M -41M -10M -37M -72M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0 0 0 0 -7000 -2M
acquisitionsNet 0 0 0 0 0 0 10M 10M 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 10M 0 0 0
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 2M -130 000 0 0 0 0 5M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 0 0 0 0 0
netCashUsedProvidedByFinancingActivities 2M -130 000 0 0 0 0 5M 0 0
effectOfForexChangesOnCash 0 0 -6000 0 -2000 -4000 8000 0 3000 1000 3000 -3000 4000 -7000
netChangeInCash 2M -633 000 -4M -2M -1M -2M -6M 3M -2M -6M -41M -10M -4M -44M
cashAtEndOfPeriod 5M 3M 3M 3M 5M 6M 8M 9M 6M 7M 13M 20M 54M 58M
cashAtBeginningOfPeriod 3M 4M 8M 5M 6M 8M 13M 6M 7M 13M 54M 30M 58M 103M
operatingCashFlow -264 000 -503 000 -4M -2M -1M -2M -21M -7M -7M -6M -41M -10M -37M -72M
capitalExpenditure 0 0 0 0 0 0 0 0 0 0 0 0 -7000 -2M
freeCashFlow -264 000 -503 000 -4M -2M -1M -2M -21M -7M -7M -6M -41M -10M -37M -74M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-04 2024-03-05 2023-03-22 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 1M 2M
netCashProvidedByInvestingActivities 0 10M 0 1M 18 000
netDebtIssuance 0 0 0 0 4M
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 4M
netStockIssuance 0 5M 29 000 31M 24M
netCommonStockIssuance 0 5M 29 000 31M 24M
commonStockIssuance 0 5M 29 000 31M 24M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 282 000 331 000
netCashProvidedByFinancingActivities 0 5M 29 000 31M 28M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

Press-releases

Show financial reports only

2026-04-01 ET
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
2026-02-17 12:00 ET
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
2026-01-05 21:01 ET
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
2025-09-23 20:01 ET
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
2024-12-17 ET
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
2024-08-07 ET
Regina Graul, Ph.D., Promoted to Chief Executive Officer
2023-12-04 13:00 ET
Cyclerion Appoints Regina Graul, Ph.D., as President
2023-11-30 23:16 ET
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
2023-07-31 11:00 ET
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
2023-07-31 ET
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
2023-06-01 20:00 ET
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
2023-05-15 17:00 ET
Cyclerion Announces Reverse Stock Split
2023-05-11 22:00 ET
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
2023-05-11 22:00 ET
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
2023-04-03 11:30 ET
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
2023-03-27 11:00 ET
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
2023-03-22 20:40 ET
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
2022-11-22 12:00 ET
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
2022-10-06 12:00 ET
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
2022-08-09 20:00 ET
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
2022-07-28 11:00 ET
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
2022-07-26 11:00 ET
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
2022-06-28 13:00 ET
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
2022-06-22 12:30 ET
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
2022-06-17 12:00 ET
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
2022-06-10 11:00 ET
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
2022-06-06 11:00 ET
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
2022-05-04 20:01 ET
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
2022-02-24 21:01 ET
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
2022-02-23 13:00 ET
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
2022-01-26 13:00 ET
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
2021-11-11 22:32 ET
Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference
2021-11-09 21:01 ET
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
2021-09-22 12:00 ET
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
2021-09-08 12:00 ET
Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
2021-08-23 21:00 ET
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
2021-07-29 21:00 ET
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
2021-07-22 20:30 ET
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)
2021-07-08 23:22 ET
Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership
2021-07-08 20:30 ET
Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
2021-06-04 12:00 ET
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
2021-06-04 12:00 ET
Cyclerion Therapeutics Announces $18 Million Private Placement
2021-06-04 ET
Cyclerion Therapeutics Announces $18 Million Private Placement
2021-05-27 20:30 ET
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
2021-05-25 11:00 ET
Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
2021-04-27 13:00 ET
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
2021-04-26 11:00 ET
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
2021-04-21 11:30 ET
Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
2021-04-20 11:00 ET
Cyclerion Therapeutics to Host Pipeline Update Webinar
2021-03-30 11:00 ET
AavantiBio Appoints Dr. Christopher Wright as Chief Medical Officer
2021-03-24 20:05 ET
TransMedics Appoints Stephanie Lovell to Board of Directors
2021-03-18 21:00 ET
Cyclerion Therapeutics Announces Departure of Chief Medical Officer
2021-02-25 12:00 ET
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
2021-01-25 12:00 ET
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
2021-01-04 12:00 ET
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
2020-12-21 12:30 ET
Cyclerion Announces Leadership Transitions
2020-11-05 12:00 ET
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
2020-10-14 11:00 ET
Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
2020-10-14 11:00 ET
Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
2020-09-04 11:00 ET
Cyclerion to Participate at Upcoming September 2020 Investor Conferences
2020-08-25 11:00 ET
Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
2020-08-03 13:25 ET
Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
2020-07-30 13:00 ET
Cyclerion Therapeutics Completes $24 Million Private Placement
2020-07-30 ET
Cyclerion Therapeutics Completes $24 Million Private Placement
2020-07-17 11:00 ET
Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit
2020-06-18 20:01 ET
Cyclerion to Host Webcast Investor Event on July 9, 2020
2020-04-10 11:00 ET
Cyclerion Updates Corporate Progress
2020-01-13 12:00 ET
Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
2019-12-23 12:00 ET
Cyclerion to Present at the J.P. Morgan Healthcare Conference
2019-11-27 12:00 ET
Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
2019-10-30 11:31 ET
Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
2019-10-30 11:30 ET
Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
2019-10-08 12:00 ET
Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings
2019-09-10 12:00 ET
Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17

SEC forms

Show financial reports only

SEC form 8
2026-02-17 12:21 ET
Cyclerion Therapeutics published news for 2025 q4
SEC form 8
2026-02-17 12:21 ET
Cyclerion Therapeutics published news for 2025 q4
SEC form 8
2026-01-06 13:33 ET
Cyclerion Therapeutics published news for 2025 q4
SEC form 8
2026-01-06 13:33 ET
Cyclerion Therapeutics published news for 2025 q4
SEC form 8
2026-01-06 13:33 ET
Cyclerion Therapeutics published news for 2025 q4
SEC form 10
2025-11-12 16:30 ET
Cyclerion Therapeutics reported for 2025 q3
SEC form 8
2025-09-23 20:14 ET
Cyclerion Therapeutics published news for 2025 q2
SEC form 8
2025-09-23 20:14 ET
Cyclerion Therapeutics published news for 2025 q2
SEC form 8
2025-09-23 20:14 ET
Cyclerion Therapeutics published news for 2025 q2
SEC form 10
2025-08-05 20:30 ET
Cyclerion Therapeutics reported for 2025 q2
SEC form 8
2025-06-18 20:41 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 8
2025-05-07 21:25 ET
Cyclerion Therapeutics published news for 2025 q1
SEC form 10
2025-05-06 20:15 ET
Cyclerion Therapeutics reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Cyclerion Therapeutics reported for 2025 q1
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 8
2025-03-25 20:40 ET
Cyclerion Therapeutics published news for 2024 q4
SEC form 10
2025-03-04 21:15 ET
Cyclerion Therapeutics reported for 2024 q4
SEC form 10
2025-03-04 00:00 ET
Cyclerion Therapeutics reported for 2024 q4
SEC form 10
2024-11-14 16:30 ET
Cyclerion Therapeutics reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Cyclerion Therapeutics reported for 2024 q3
SEC form 10
2024-08-07 00:00 ET
Cyclerion Therapeutics reported for 2024 q2
SEC form 10
2024-05-07 00:00 ET
Cyclerion Therapeutics reported for 2024 q1
SEC form 10
2024-03-05 00:00 ET
Cyclerion Therapeutics reported for 2023 q4
SEC form 10
2023-11-13 00:00 ET
Cyclerion Therapeutics reported for 2023 q3
SEC form 10
2023-07-28 16:48 ET
Cyclerion Therapeutics reported for 2023 q2
SEC form 10
2023-07-28 00:00 ET
Cyclerion Therapeutics reported for 2023 q2
SEC form 6
2023-07-19 17:27 ET
Cyclerion Therapeutics published news for 2023 q2
SEC form 6
2023-07-12 16:12 ET
Cyclerion Therapeutics published news for 2023 q2
SEC form 6
2023-06-27 16:53 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-06-09 17:23 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 19:37 ET
Cyclerion Therapeutics reported for 2023 q1
SEC form 6
2023-05-11 19:26 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-04-03 16:32 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-04-03 09:53 ET
Cyclerion Therapeutics published news for 2023 q1
SEC form 6
2023-03-22 17:00 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 10
2023-03-22 16:55 ET
Cyclerion Therapeutics reported for 2022 q4
SEC form 6
2023-03-22 16:52 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 10
2023-03-22 00:00 ET
Cyclerion Therapeutics reported for 2022 q4
SEC form 8
2023-03-22 00:00 ET
Cyclerion Therapeutics published news for 2022 q4
SEC form 6
2022-11-29 16:00 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 6
2022-11-22 16:31 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 17:00 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Cyclerion Therapeutics reported for 2022 q3
SEC form 6
2022-10-06 08:01 ET
Cyclerion Therapeutics published news for 2022 q3
SEC form 6
2022-09-30 17:15 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 16:04 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-08-09 16:01 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Cyclerion Therapeutics reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-28 09:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-26 16:30 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-07-26 07:00 ET
Cyclerion Therapeutics published news for 2022 q2
SEC form 6
2022-06-15 16:03 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 07:01 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-06-03 16:00 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 16:07 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-05-04 16:01 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Cyclerion Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 6
2022-04-26 07:52 ET
Cyclerion Therapeutics published news for 2022 q1
SEC form 10
2022-02-24 16:06 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 16:01 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Cyclerion Therapeutics published news for 2021 q4
SEC form 6
2021-12-10 16:32 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 16:31 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 16:31 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 16:01 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 16:01 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-10-28 16:50 ET
Cyclerion Therapeutics published news for 2021 q3
SEC form 6
2021-09-30 09:01 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:40 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:37 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-27 16:31 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-08-19 16:51 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 10
2021-07-29 16:58 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-07-29 16:54 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Cyclerion Therapeutics published news for 2021 q2
SEC form 6
2021-06-28 17:27 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:25 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:22 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:17 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:14 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:11 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-28 17:05 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-25 16:31 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-06-04 16:37 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-19 18:16 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-06 21:27 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-05-04 16:39 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 10
2021-04-30 16:04 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 07:01 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-27 09:20 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-04-26 08:58 ET
Cyclerion Therapeutics published news for 2021 q1
SEC form 6
2021-03-19 06:01 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-03-18 17:00 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 07:35 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 07:31 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 17:49 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 17:45 ET
Cyclerion Therapeutics published news for 2020 q4
SEC form 6
2020-12-30 21:53 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-12-21 16:35 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 07:00 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-10-14 07:22 ET
Cyclerion Therapeutics published news for 2020 q3
SEC form 6
2020-10-01 07:21 ET
Cyclerion Therapeutics published news for 2020 q3